CA2985161A1 - Nouveaux ethynes d'aroyl-hydrazide amidoheteroaryliques - Google Patents

Nouveaux ethynes d'aroyl-hydrazide amidoheteroaryliques Download PDF

Info

Publication number
CA2985161A1
CA2985161A1 CA2985161A CA2985161A CA2985161A1 CA 2985161 A1 CA2985161 A1 CA 2985161A1 CA 2985161 A CA2985161 A CA 2985161A CA 2985161 A CA2985161 A CA 2985161A CA 2985161 A1 CA2985161 A1 CA 2985161A1
Authority
CA
Canada
Prior art keywords
methyl
pyridin
formula
alkyl
hydrazinocarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2985161A
Other languages
English (en)
Inventor
Hemant Ashvinbhai Chokshi
Sabbirhusen Yusufbhai CHIMANWALA
Varun Anilkumar MEHTA
Prabal Sengupta
Chitturi Trinadha RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of CA2985161A1 publication Critical patent/CA2985161A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne de nouveaux éthynes d'aroyl-hydrazide amidohétéroaryliques utilisés comme inhibiteurs de tyrosines kinases, leur procédé de préparation et l'utilisation de ces composés pour la préparation de compositions pharmaceutiques pour le traitement thérapeutique de troubles associés aux tyrosines kinases chez des êtres humains.
CA2985161A 2015-05-18 2016-05-18 Nouveaux ethynes d'aroyl-hydrazide amidoheteroaryliques Abandoned CA2985161A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1953/MUM/2015 2015-05-18
IN1953MU2015 2015-05-18
PCT/IN2016/050142 WO2016185490A1 (fr) 2015-05-18 2016-05-18 Nouveaux éthynes d'aroyl-hydrazide amidohétéroaryliques

Publications (1)

Publication Number Publication Date
CA2985161A1 true CA2985161A1 (fr) 2016-11-24

Family

ID=57319598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2985161A Abandoned CA2985161A1 (fr) 2015-05-18 2016-05-18 Nouveaux ethynes d'aroyl-hydrazide amidoheteroaryliques

Country Status (13)

Country Link
US (1) US10150733B2 (fr)
EP (1) EP3297991B1 (fr)
JP (1) JP6689887B2 (fr)
KR (1) KR20180011772A (fr)
CN (1) CN107709300A (fr)
AU (1) AU2016263311A1 (fr)
BR (1) BR112017024633A2 (fr)
CA (1) CA2985161A1 (fr)
EA (1) EA032697B1 (fr)
ES (1) ES2774501T3 (fr)
MX (1) MX2017014752A (fr)
WO (1) WO2016185490A1 (fr)
ZA (1) ZA201707664B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037697B1 (ru) * 2016-06-02 2021-05-12 Сан Фарма Адвансед Ресёрч Компани Лимитед Лечение болезни паркинсона
MY193754A (en) * 2016-06-02 2022-10-27 Sun Pharma Advanced Res Co Ltd Treatment for parkinson's disease
CA3056356A1 (fr) 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Nouvelle dispersion amorphe d'acide cyclopropanecarboxylique (5-{5-[ n'-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl] -2-methyl-phenylethynyl}-pyridin-2-yl) amide
WO2019241504A1 (fr) 2018-06-15 2019-12-19 Handa Pharmaceuticals, Llc Sels d'inhibiteurs de kinases et compositions associées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2023933A4 (fr) * 2006-05-08 2011-02-23 Ariad Pharma Inc Composés d'hétéroaryle acétylénique
CN103370324B (zh) * 2010-12-27 2016-05-18 孙树萍 作为蛋白激酶抑制剂的芳炔类衍生物及其医疗用途
KR101892574B1 (ko) * 2011-01-21 2018-08-28 썬 파마 어드밴스트 리서치 컴패니 리미티드 디아릴아세틸렌 히드라지드 함유 티로신 키나제 억제제
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines

Also Published As

Publication number Publication date
EA201792445A1 (ru) 2018-04-30
EP3297991B1 (fr) 2020-01-29
BR112017024633A2 (pt) 2018-07-31
ZA201707664B (en) 2019-08-28
EP3297991A1 (fr) 2018-03-28
CN107709300A (zh) 2018-02-16
EP3297991A4 (fr) 2018-11-21
JP6689887B2 (ja) 2020-04-28
KR20180011772A (ko) 2018-02-02
WO2016185490A1 (fr) 2016-11-24
MX2017014752A (es) 2018-03-23
EA032697B1 (ru) 2019-07-31
AU2016263311A1 (en) 2017-11-30
JP2018515550A (ja) 2018-06-14
US10150733B2 (en) 2018-12-11
ES2774501T3 (es) 2020-07-21
US20180127372A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
JP7109012B2 (ja) 血漿カリクレインインヒビターとしてのピラゾール誘導体
CN109790167B (zh) Sgc刺激剂
CA2592118C (fr) Derives d'uree en tant que modulateurs d'enzyme
CN105358550B (zh) 组蛋白脱乙酰基酶抑制剂
CN103153980B (zh) 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
JP2021185138A (ja) 血漿カリクレイン阻害剤としてのｎ−（（ヘタ）アリールメチル）−ヘテロアリール−カルボキサミド化合物
CN102239150A (zh) 作为用于增殖性疾病治疗的蛋白激酶抑制剂的新型吲唑衍生物或其药学上可接受的盐以及含有其作为活性成分的药物组合物
EP3297991B1 (fr) Nouveaux éthynes d'aroyl-hydrazide amidohétéroaryliques
WO2012034363A1 (fr) Composés d'inhibiteurs de la voie de hedgehog, compositions pharmaceutiques les contenant et leurs utilisations
CA2785923A1 (fr) Composes therapeutiques et procedes d'utilisation associes
PT1107964E (pt) Derivados de isoquinolina com actividade inibidora da angiogénese
WO2012098416A1 (fr) Inhibiteurs de tyrosine kinase contenant un diarylacétylène hydrazide
TW201113268A (en) Disubstituted phthalazine hedgehog pathway antagonists
CN111051300B (zh) 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物
JP2017537948A (ja) Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体
CN109310679A (zh) 包含组蛋白脱乙酰酶抑制剂的组合
JP2014533713A (ja) Ｅｐ２受容体拮抗薬としての新規の２ｈ−インダゾール
CN104958294A (zh) 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
WO2009086731A1 (fr) Nouveaux composés de benzimidazole
JP7163180B2 (ja) ３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用
JP5799117B2 (ja) ウラシル誘導体からなる医薬
CN106535894A (zh) 用于癌症治疗的mcl‑1调节化合物
CN111138426B (zh) 吲唑类激酶抑制剂及其用途
US20220162186A1 (en) Prostaglandin receptor ep2 antagonists, derivatives, and uses related thereto
EA043363B1 (ru) Ингибиторы rho-ассоциированной суперспираль содержащей протеинкиназы

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301